These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20074280)

  • 21. The Future of IL-1 Targeting in Kidney Disease.
    Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
    Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.
    Goldbach-Mansky R; Kastner DL
    J Allergy Clin Immunol; 2009 Dec; 124(6):1141-9; quiz 1150-1. PubMed ID: 20004775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-1 pathways in inflammation and human diseases.
    Gabay C; Lamacchia C; Palmer G
    Nat Rev Rheumatol; 2010 Apr; 6(4):232-41. PubMed ID: 20177398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
    Lipsker D; Lenormand C
    Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives.
    Thomas GK; Bonaventura A; Vecchié A; van Tassell B; Imazio M; Klein A; Luis SA; Abbate A
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):503-510. PubMed ID: 37163222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.
    Kahlenberg JM
    Curr Opin Rheumatol; 2016 May; 28(3):197-203. PubMed ID: 26859478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome.
    Quartier P
    Open Access Rheumatol; 2011; 3():9-18. PubMed ID: 27790000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anakinra in children and adults with Still's disease.
    Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
    Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
    Emmi G; Urban ML; Imazio M; Gattorno M; Maestroni S; Lopalco G; Cantarini L; Prisco D; Brucato A
    Curr Cardiol Rep; 2018 Jun; 20(8):61. PubMed ID: 29904899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. At the horizon of innovative therapy in rheumatology: new biologic agents.
    Finckh A; Gabay C
    Curr Opin Rheumatol; 2008 May; 20(3):269-75. PubMed ID: 18388517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is IL-1 a good therapeutic target in the treatment of arthritis?
    Burger D; Dayer JM; Palmer G; Gabay C
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
    Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?
    van Royen-Kerkhof A; Vastert BS; Swart JF; Wulffraat NM
    Immunotherapy; 2014; 6(1):1-3. PubMed ID: 24341875
    [No Abstract]   [Full Text] [Related]  

  • 34. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
    Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
    Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases.
    Pazyar N; Feily A; Yaghoobi R
    Curr Clin Pharmacol; 2012 Nov; 7(4):271-5. PubMed ID: 22794157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.
    Ozen S; Demir S
    Paediatr Drugs; 2017 Aug; 19(4):303-311. PubMed ID: 28497352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammasome and cytokine blocking strategies in autoinflammatory disorders.
    Moll M; Kuemmerle-Deschner JB
    Clin Immunol; 2013 Jun; 147(3):242-75. PubMed ID: 23697917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of autoinflammatory syndromes.
    Gattorno M; Martini A
    Curr Opin Pediatr; 2010 Dec; 22(6):771-8. PubMed ID: 20966753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).
    Van Tassell BW; Buckley LF; Carbone S; Trankle CR; Canada JM; Dixon DL; Abouzaki N; Oddi-Erdle C; Biondi-Zoccai G; Arena R; Abbate A
    Clin Cardiol; 2017 Sep; 40(9):626-632. PubMed ID: 28475816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.